Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The European neurostimulation device market is growing modestly, and will be buoyed over the forecast period by the ongoing launch of premium-priced products.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for neurostimulation devices in France, Germany, Italy, Spain and the UK across a 10-year period.
What are the major growth areas driving the European neurostimulation market?
How much growth will be experienced by more mature segments such as SCS?
How will new technologies affect the SCS, DBS, SNS and VNS markets?
What indications are approved for neurostimulation therapy in Europe vs. the US?
What additional patient populations are treated with neurostimulation devices in Europe?
Will new indications arise over the forecast period?
Already a Client? Log in to access this report.
Michael Tian is a senior analyst within the Cardiovascular Medtech Insights team at Decision Resources Group and is an expert in interventional cardiology, cardiac surgery, vascular access, and interventional oncology device markets. Michael spends much of his time exploring and translating large claims and hospital purchase datasets into intriguing stories within the global MedTech market, and he is always looking for the next challenging question to tackle. Michael holds a in Physiology and Neuroscience from the University of Toronto.